Q - Ceribell,
For the period ended Jun 30, 2025. Filed Aug 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 5, 2025
What changed in Management’s Discussion and Analysis?
Read the current filingPrevious report: 10-Q
Period ended 2025-03-31; filed 2025-05-08.
0000950170-25-067097
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of OperationsCurrent report: 10-Q
Period ended 2025-06-30; filed 2025-08-05.
0000950170-25-103142
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of OperationsThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 102 previous paragraphs and 106 current paragraphs.
81 unchanged; 20 reworded; 4 added; 0 removed; 1 previous and 1 current paragraphs rearranged.
Tables are not compared: 3 previous and 5 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
Added paragraphs (4)
Current report
Results of Operations for the Three and Six Months Ended June 30, 2025 and 2024
Current report
Research and development expenses for the increased $2.8 million, or 45%, for the six months ended June 30, 2025, compared to the same period of fiscal year 2024. The increase was primarily due to an increase of $1.7 million in personnel and related expenses directly associated with an increase in headcount, as well as an increase of $1.1 million in clinical study and professional expenses.
Current report
Sales and marketing expenses increased $14.2 million, or 67%, for the six months ended June 30, 2025, compared to the same period of fiscal year 2024. The increase was primarily due to an increase in personnel and related expenses directly associated with an increase in headcount.
Current report
General and administrative expenses increased $6.4 million, or 43%, for the six months ended June 30, 2025, compared to the same period of fiscal year 2024. The increase was primarily due to an increase of $3.6 million in personnel and related expenses directly associated with an increase in headcount, as well as an increase of $2.4 million in legal, accounting, and professional service fees related to our transition to a public company and costs associated with intellectual property enforcement activities, including a new patent infringement claim initiated during the quarter.
Reworded paragraphs (20)
Previous wording
As of March 31, 2025, we had an accumulated deficit of $179.7 million. To date, we have funded our operations primarily through proceeds from the sale of shares of our stock, including common stock and redeemable convertible preferred stock, term loan proceeds, and cash generated from the sale of headbands and subscriptions. As of March 31, 2025, we had $182.7 million in cash and cash equivalents and short term marketable securities. Based on our current operating plan, we believe that the net proceeds from our IPO, together with the expected cash generated from revenue transactions with customers and our existing cash and cash equivalents, will be sufficient to fund our planned operating expenses and capital expenditure requirements for at least the next 12 months. We have based this estimate on assumptions that may prove to be wrong, and we could deplete our capital resources sooner than we expect. We may experience lower than expected cash generated from operating activities or greater than expected capital expenditures, cost of revenue, or operating expenses, and may need to raise additional capital to fund operations, further research and development activities, or acquire, invest in, or in-license other businesses, assets, or technologies.
Current wording
As of June 30, 2025, we had an accumulated deficit of $193.4 million. To date, we have funded our operations primarily through proceeds from the sale of shares of our stock, including common stock and redeemable convertible preferred stock, term loan proceeds, and cash generated from the sale of headbands and subscriptions. As of June 30, 2025, we had $177.4 million in cash and cash equivalents and marketable securities. Based on our current operating plan, we believe that the net proceeds from our IPO, together with the expected cash generated from revenue transactions with customers and our existing cash and cash equivalents, will be sufficient to fund our planned operating expenses and capital expenditure requirements for at least the next 12 months. We have based this estimate on assumptions that may prove to be wrong, and we could deplete our capital resources sooner than we expect. We may experience lower than expected cash generated from operating activities or greater than expected capital expenditures, cost of revenue, or operating expenses, and may need to raise additional capital to fund operations, further research and development activities, or acquire, invest in, or in-license other businesses, assets, or technologies.
Previous wording
Gross profit, or revenue less cost of revenue, and gross margin, or gross profit as a percentage of revenue, have been and will continue to be affected by various factors that may cause gross margins to fluctuate. These include the product mix between product and subscription revenues, potential changes to sales prices, the timing of our acquisition of new customers, renewals of and follow-on sales to existing customers, costs associated with third-party hosting fees, costs associated with third party manufacturing and supply chain purchases of inventory, and other direct costs such as tariffs and shipping. We expect our product inventory, currently located within the United States, to enable sufficient supply of finished goods through at least the third quarter of 2025. We do not expect any material impact to our financial results from incremental tariffs until at least the fourth quarter of 2025. Our gross margin may fluctuate from period to period, based upon the factors described above and in the section titled “Risk Factors” included elsewhere in this Quarterly Report on Form 10-Q.
Current wording
Gross profit, or revenue less cost of revenue, and gross margin, or gross profit as a percentage of revenue, have been and will continue to be affected by various factors that may cause gross margins to fluctuate. These include the product mix between product and subscription revenues, potential changes to sales prices, the timing of our acquisition of new customers, renewals of and follow-on sales to existing customers, costs associated with third-party hosting fees, costs associated with third party manufacturing and supply chain purchases of inventory, and other direct costs such as tariffs and shipping. We expect our product inventory, currently located within the United States, to enable sufficient supply of finished goods through at least the end of 2025. We do not expect any material impact to our financial results from incremental tariffs until at least the fourth quarter of 2025. Our gross margin may fluctuate from period to period, based upon the factors described above and in the section titled “Risk Factors” included elsewhere in this Quarterly Report on Form 10-Q.
Previous wording
Comparison of the Three Months Ended March 31, 2025 and 2024
Current wording
Comparison of the Three and Six Months Ended June 30, 2025 and 2024
Previous wording
Product revenue for the three months ended March 31, 2025, increased $4.6 million, or 41%, compared to the same periods of fiscal year 2024. Product revenue growth is primarily driven by the addition of new customers and an increase in utilization of headbands and resulting headband sales, driven by continued customer education that resulted in increased awareness and adoption of our products.
Current wording
Product revenue for the three and six months ended June 30, 2025, increased $4.3 million and $8.9 million, or 38% and 39%, respectively, compared to the same periods of fiscal year 2024. Product revenue growth is primarily driven by the addition of new customers and an increase in utilization of headbands and resulting headband sales, driven by continued customer education that resulted in increased awareness and adoption of our products.
Previous wording
Subscription revenue for the three months ended March 31, 2025, increased $1.5 million, or 45%, compared to the same periods of fiscal year 2024. Subscription revenue growth is primarily driven by an increase in adoption of subscriptions.
Current wording
Subscription revenue for the three and six months ended June 30, 2025, increased $1.5 million and $3.1 million, or 41% and 43%, respectively, compared to the same periods of fiscal year 2024. Subscription revenue growth is primarily driven by an increase in adoption of subscriptions.
Previous wording
Product cost of revenue for the three months ended March 31, 2025, increased $0.4 million, or 21%, compared to the same periods of fiscal year 2024. The increase in cost of goods sold for products was primarily due to an increase in headband sales to new and existing active accounts, partially offset by a decrease in the cost of goods sold per unit, as non-variable costs are allocated among a larger number of units.
Current wording
Product cost of revenue for the three and six months ended June 30, 2025, increased $0.3 million and $0.7 million, or 16% and 18%, respectively, compared to the same periods of fiscal year 2024. The increase in cost of goods sold for products was primarily due to an increase in headband sales to new and existing active accounts, partially offset by a decrease in the cost of goods sold per unit, as non-variable costs are allocated among a larger number of units.
Previous wording
Subscription cost of revenue for the three months ended March 31, 2025, increased $0.01 million, or 9%, compared to the same periods of fiscal year 2024. The increase in subscription cost of revenue was primarily due to increased hosting costs for new active accounts for subscriptions and incremental recorder depreciation associated with new subscriptions.
Current wording
Subscription cost of revenue for three and six months ended June 30, 2025, increased $0.04 million and $0.05 million, or 35% and 22%, respectively, compared to the same periods of fiscal year 2024. The increase in subscription cost of revenue was primarily due to increased hosting costs for new active accounts for subscriptions and incremental recorder depreciation associated with new subscriptions.
Previous wording
Gross profit increased $5.7 million, or 46%, for the three months ended March 31, 2025, compared to the same period of fiscal year 2024. The increase is primarily due to increased revenue and decreased cost of goods sold per unit, as non-variable costs are allocated among a larger number of units.
Current wording
Gross profit for the three and six months ended June 30, 2025 increased $5.5 million and $11.2 million, or 42% and 44%, respectively, compared to the same period of fiscal year 2024. The increase is primarily due to increased revenue and decreased cost of goods sold per unit, as non-variable costs are allocated among a larger number of units.
Previous wording
Research and development expenses increased $1.3 million, or 42%, for the three months ended March 31, 2025, compared to the same period of fiscal year 2024. The increase was primarily due to an increase of $0.7 million in personnel and related expenses directly associated with an increase in headcount, as well as an increase of $0.4 million in clinical study and professional expenses.
Current wording
Research and development expenses for the increased $1.6 million, or 48%, for the three months ended June 30, 2025, compared to the same period of fiscal year 2024. The increase was primarily due to an increase of $1.1 million in personnel and related expenses directly associated with an increase in headcount, as well as an increase of $0.6 million in clinical study and professional expenses.
Previous wording
Sales and marketing expenses increased $7.5 million, or 71%, for the three months ended March 31, 2025, respectively, compared to the same periods of fiscal year 2024. The increase was primarily due to an increase in personnel and related expenses directly associated with an increase in headcount.
Current wording
Sales and marketing expenses increased $6.7 million, or 63%, for the three months ended June 30, 2025, compared to the same period of fiscal year 2024. The increase was primarily due to an increase in personnel and related expenses directly associated with an increase in headcount.
Previous wording
General and administrative expenses increased $2.7 million, or 37%, for the three months ended March 31, 2025, compared to the same period of fiscal year 2024. The increase was primarily due to an increase of $1.7 million in personnel and related expenses directly associated with an increase in headcount, as well as an increase of $0.6 million in legal, accounting, and professional service fees related to our transition to a public company.
Current wording
General and administrative expenses increased $3.7 million, or 49%, for the three months ended June 30, 2025, compared to the same period of fiscal year 2024. The increase was primarily due to an increase of $1.7 million in personnel and related expenses directly associated with an increase in headcount, as well as an increase of $1.8 million in legal, accounting, and professional service fees related to our transition to a public company and costs associated with intellectual property enforcement activities, including a new patent infringement claim initiated during the quarter.
Previous wording
Interest and other income (expense), net increased $1.5 million for the three months ended March 31, 2025 as compared to the same period for fiscal year 2024. The increase in interest income was primarily due to higher balances of cash equivalents and marketable securities, resulting from the investment of IPO proceeds.
Current wording
Interest and other income (expense), net increased $1.8 million for the three months ended June 30, 2025, compared to the same period for fiscal year 2024. The increase in interest income was primarily due to higher balances of cash equivalents and marketable securities, resulting from the investment of IPO proceeds.
Previous wording
Net cash used in operating activities during the three months ended March 31, 2024, consisted primarily of our net loss of $8.5 million, offset by non-cash charges of stock-based compensation of $0.8 million and depreciation and amortization of $0.3 million. Additionally we had a net increase in operating assets of $0.6 million and a net decrease in operating liabilities of $1.5 million. Net operating assets increased due to the timing of inventory purchases and accounts receivable due to the overall increase in sales in the three months ended March 31, 2024. Net operating liabilities decreased primarily due to timing of payments.
Current wording
Net cash used in operating activities during the six months ended June 30, 2025, consisted primarily of our net loss of $26.4 million, offset by non-cash charges of stock-based compensation of $5.5 million, and depreciation and amortization of $0.7 million. Additionally we had a net decrease in operating assets of $0.2 million and a net increase in operating liabilities of $1.4 million. Net operating assets decreased due to decreases in prepaid expenses and inventory due to lower inventory purchases in the six months ended June 30, 2025. Net operating liabilities decreased primarily due to timing of payments.
Previous wording
Net cash used in operating activities during the three months ended March 31, 2025, consisted primarily of our net loss of $12.8 million, offset by non-cash charges of stock-based compensation of $2.3 million, and depreciation and amortization of $0.3 million. Additionally we had a net increase in operating assets of $0.1 million and a net decrease in operating liabilities of $1.3 million. Net operating assets increased due to increases in accounts receivable and contract costs due to the overall increase in sales in the three months ended March 31, 2025. Net operating liabilities decreased primarily due to timing of payments.
Current wording
Net cash used in operating activities during the six months ended June 30, 2024, consisted primarily of our net loss of $17.5 million, non-cash charges of stock-based compensation of $1.8 million, and a net decrease in operating liabilities of $1.0 million. Net operating liabilities decreased primarily due to timing of payments.
Previous wording
Net cash used in investing activities during the three months ended March 31, 2025 and 2024 was $29.6 million and $0.1 million, respectively, and consisted of purchases of marketable securities during the three months ended March 31, 2025, and purchases of equipment and recorders provided to customers for both periods.
Current wording
Net cash used in investing activities during the six months ended June 30, 2025 and 2024 was $137.3 million and $1.3 million, respectively, and consisted of purchases of marketable securities during the six months ended June 30, 2025, and purchases of equipment and recorders provided to customers for both periods.
Previous wording
Net cash provided in financing activities during the three months ended March 31, 2025, consisted of proceeds from the exercise of options, and offset by debt issuance costs.
Current wording
Net cash provided in financing activities during the six months ended June 30, 2025, consisted of proceeds from the exercise of options, and offset by debt issuance costs.
Previous wording
Net cash provided in financing activities during the three months ended March 31, 2024, consisted primarily of $0.1 million in proceeds from the exercise of options and $7.6 million in net proceeds from debt issuance.
Current wording
Net cash provided in financing activities during the six months ended June 30, 2024, consisted primarily of $0.6 million in proceeds from the exercise of options, $0.5 million in payments of deferred initial public offering costs, and $7.6 million in net proceeds from debt issuance.
Previous wording
As of March 31, 2025, our principal sources of liquidity consisted of $182.7 million of cash and cash equivalents and short term marketable securities and $20.0 million of term loans.
Current wording
As of June 30, 2025, our principal sources of liquidity consisted of $177.4 million of cash and cash equivalents and marketable securities and $20.0 million of term loans.
Previous wording
Operating leases — As of March 31, 2025, estimated contractual obligations for operating lease payments were $2.3 million due within 22 months.
Current wording
Operating leases — As of June 30, 2025, estimated contractual obligations for operating lease payments were $2.0 million due within 19 months.
Previous wording
Information about our significant accounting policies and how estimates are involved in the preparation of our financial statements are described in our Annual Report on Form 10-K filed with the SEC on February 25, 2025. There have been no material changes to our significant accounting policies and estimates during the three months ended March 31, 2025.
Current wording
Information about our significant accounting policies and how estimates are involved in the preparation of our financial statements are described in our Annual Report on Form 10-K filed with the SEC on February 25, 2025. There have been no material changes to our significant accounting policies and estimates during the six months ended June 30, 2025.
Rearranged current paragraphs (1)
Current report — wording carried from elsewhere
Interest and other income (expense), net increased $3.3 million for the six months ended June 30, 2025, compared to the same period for fiscal year 2024. The increase in interest income was primarily due to higher balances of cash equivalents and marketable securities, resulting from the investment of IPO proceeds.
Rearranged previous paragraphs (1)
Previous report — wording carried elsewhere
Results of Operations for the Three Months Ended March 31, 2025 and 2024